These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 22233347)
41. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270 [TBL] [Abstract][Full Text] [Related]
42. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Bellia A; Rizza S; Galli A; Fabiano R; Donadel G; Lombardo MF; Cardillo C; Sbraccia P; Tesauro M; Lauro D Atherosclerosis; 2010 May; 210(1):199-201. PubMed ID: 20018286 [TBL] [Abstract][Full Text] [Related]
43. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Cheng-Lai A Heart Dis; 2003; 5(1):72-8. PubMed ID: 12549990 [TBL] [Abstract][Full Text] [Related]
44. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Fabbri G; Maggioni AP Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394 [TBL] [Abstract][Full Text] [Related]
46. Does rosuvastatin offer therapeutic potential in autoimmune thyroiditis in nonobese diabetic mice? Mori K; Nakagawa Y; Hoshikawa S; Ozaki H; Ito S; Yoshida K Clin Immunol; 2009 Mar; 130(3):375-7. PubMed ID: 19019736 [No Abstract] [Full Text] [Related]
47. Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction. Xu Y; Tang T; Ding Y; Yao R; Xie J; Liao M; Xiao H; Chen Y; Yu X; Fu M; Liao Y; Zhao G; Cheng X Am J Med Sci; 2010 Aug; 340(2):121-7. PubMed ID: 20588182 [TBL] [Abstract][Full Text] [Related]
49. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Andreou I; Tousoulis D; Miliou A; Tentolouris C; Zisimos K; Gounari P; Siasos G; Papageorgiou N; Papadimitriou CA; Dimopoulos MA; Stefanadis C Atherosclerosis; 2010 May; 210(1):194-8. PubMed ID: 19962701 [TBL] [Abstract][Full Text] [Related]
50. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. Verhulst A; D'Haese PC; De Broe ME J Am Soc Nephrol; 2004 Sep; 15(9):2249-57. PubMed ID: 15339974 [TBL] [Abstract][Full Text] [Related]
51. Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia. Daskalopoulou SS; Mikhailidis DP Curr Med Res Opin; 2006 Oct; 22(10):2037-9. PubMed ID: 17022863 [TBL] [Abstract][Full Text] [Related]
52. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Desjardins F; Sekkali B; Verreth W; Pelat M; De Keyzer D; Mertens A; Smith G; Herregods MC; Holvoet P; Balligand JL Eur Heart J; 2008 Jan; 29(1):128-37. PubMed ID: 18063594 [TBL] [Abstract][Full Text] [Related]
53. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Hirsch M; O'Donnell JC; Jones P Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502 [TBL] [Abstract][Full Text] [Related]
55. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Strandberg TE; Feely J; Sigurdsson EL; Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694 [TBL] [Abstract][Full Text] [Related]
56. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats. Engelhorn T; Doerfler A; Heusch G; Schulz R Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636 [TBL] [Abstract][Full Text] [Related]
57. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896 [TBL] [Abstract][Full Text] [Related]
58. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Kostapanos MS; Milionis HJ; Elisaf MS Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931 [TBL] [Abstract][Full Text] [Related]